Meeting Information - The shareholder meeting is scheduled for September 9, 2025 [1] - The meeting will be held at the company's conference room located at No. 2, Kexin Street, Huangpu District, Guangzhou [4] - Voting will be conducted through both on-site and online methods using the Shanghai Stock Exchange's network voting system [1][2] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange's network voting system, with specific time slots for voting on the meeting day [1][3] - The voting time for the trading system is from 9:15-9:25, 9:30-11:30, and 13:00-15:00, while the internet voting platform is available from 9:15 to 15:00 [1][3] Agenda Items - The meeting will review a proposal to temporarily adjust the use of idle funds from fundraising projects [2] - The proposal has already been approved by the fourth board of directors and the supervisory board [2] Registration Details - Shareholders must register by presenting their ID and shareholder account card at the company's securities department by September 8, 2025 [5] - Registration can also be done via mail, which must arrive by September 8, 2025 [5] Attendance - Attendees include A-share shareholders, company directors, supervisors, senior management, and appointed lawyers [7] - The company will not provide gifts, and attendees are responsible for their own travel and accommodation expenses [6]

广州安必平医药科技股份有限公司 关于 2025 年度"提质增效重回报"专项行动方案的 半年度评估报告 为积极践行"以投资者为本"的上市公司发展理念，响应上海证券交易所《关 于开展沪市公司"提质增效重回报"专项行动的倡议》，广州安必平医药科技股 份有限公司（以下简称"公司"）于 2025 年 4 月发布了《2025 年度"提质增效 重回报"行动方案》。公司根据行动方案内容，积极开展和落实各项工作，现将 一、 聚焦病理诊断领域，推动病理"四化" 公司业务主要集中在医院病理科，经过多年发展已经覆盖了诊断试剂及原料、 制片读片自动化一体机、辅助诊断人工智能软件等全产业链条。搭建完成液基细 胞学（LBP） 、聚合酶链式反应（PCR）、免疫组织化学（IHC）和荧光原位杂交（FISH） 四大病理诊断方法学，是国内方法学最全的病理诊断公司，并在各产品线进行"试 剂+自动化设备+数字化产品+人工智能辅助诊断系统"的病理诊断数智化升级。 报告期内，公司新获批 12 项诊断相关注册/备案证，截至报告期末，拥有国内超 现归属于母公司所有者的净利润-1,249.85 万元，同比下降 176.38%。受内外部 因素影响，上半年公司经营层 ...

Fundraising Overview - The company raised a total of RMB 71,327.04 million from the issuance of 23.34 million shares at a price of RMB 30.56 per share, with a net amount of RMB 63,994.55 million after deducting issuance costs of RMB 7,332.49 million [1][2] - As of June 30, 2025, the remaining balance of unused raised funds is RMB 12,935.19 million, which includes RMB 235.19 million in the fundraising account and RMB 12,700.00 million in time deposits and financial products [2][3] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure the effective management and use of raised funds, including the establishment of dedicated bank accounts for fundraising [2][3] - The company signed tripartite and quadripartite supervision agreements with its subsidiaries and the sponsoring institution to clarify the rights and obligations of all parties involved [2][3] Fund Usage - The company has not used idle raised funds to temporarily supplement working capital during the reporting period [4][5] - The company has approved the use of up to RMB 16,000 million of idle raised funds for cash management, ensuring that it does not affect the normal progress of fundraising investment plans [5][6] - As of June 30, 2025, the company has invested RMB 12,700.00 million in various financial products, including transferable large-denomination certificates of deposit and structured deposits [5][6] Project Investment - The company has not made any early investments or replacements for fundraising investment projects during the reporting period [7] - The company has approved the use of part of the raised funds for new projects, including the development of a tumor companion diagnostic technology platform and a digital pathology and intelligent application development project, with an estimated investment of RMB 6,350.00 million [5][6] Remaining Funds - The company has a remaining balance of RMB 10,732.55 million in excess raised funds, which is not applicable for permanent working capital supplementation or loan repayment [6][7]

Core Viewpoint - The company plans to temporarily lease out part of the idle space from its marketing service network upgrade project to improve operational efficiency and generate additional revenue, pending approval from the shareholders' meeting [1][3]. Group 1: Fundraising Overview - The company raised a total of 713.27 million yuan from its initial public offering (IPO) by issuing 23.34 million shares at a price of 30.56 yuan per share, with a net amount of 639.95 million yuan after deducting issuance costs of 73.32 million yuan [1][2]. - The funds raised have been fully received and verified by Zhonghui Certified Public Accountants [2]. Group 2: Fund Utilization - The fundraising plan includes a project focused on the application development of a tumor companion diagnostic technology platform, with a total investment of 491.65 million yuan allocated for this purpose [2]. - The marketing service network upgrade project has been completed and is now in use, but due to a slowdown in domestic economic growth and increased competition, some space has become temporarily idle [2][3]. Group 3: Impact of Temporary Adjustment - The decision to lease out the idle space is based on the company's current operational needs and is not expected to adversely affect normal operations or harm shareholder interests [3][4]. - This adjustment is in compliance with relevant regulations and is aimed at enhancing the efficiency of the space and stabilizing the company's operations [3][4][5]. Group 4: Review Procedures - The board of directors and the supervisory board have both approved the proposal to lease the idle space, confirming that it aligns with the company's actual situation and does not harm shareholder interests [4][5]. - The sponsor institution has also reviewed the matter and found it compliant with regulatory requirements, supporting the decision to temporarily adjust the use of the idle space [4][5].

Group 1 - The company will hold a half-year performance briefing on August 28, 2025, from 09:00 to 10:00 [1][2] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [2][3] - Investors can submit questions from August 22 to August 27, 2025, and the company will address common concerns during the briefing [1][2] Group 2 - Key participants in the briefing include the Chairman and General Manager, Mr. Cai Xiangting, and other board members [2] - Investors can access the briefing online through the Shanghai Stock Exchange Roadshow Center [2][3] - After the briefing, investors can review the main content and outcomes on the Shanghai Stock Exchange Roadshow Center website [3]

Core Points - The company has completed the fundraising project "Application Development Project Based on Tumor Companion Diagnosis Technology Platform" and will use the remaining funds of 14,800 yuan to supplement working capital [1][5] - The total amount raised from the initial public offering was 713.27 million yuan, with a net amount of 639.95 million yuan after deducting issuance costs [1][2] - The project had a planned investment of 496.65 million yuan, with an actual investment of 367.55 million yuan, resulting in a surplus of 1.48 million yuan [2][3] Fundraising Overview - The company issued 23.34 million shares at a price of 30.56 yuan per share, raising a total of 713.27 million yuan [1][2] - The funds were stored in a dedicated account and managed under a regulatory agreement with the underwriter and the bank [2] Project Details - The project aimed to develop applications based on tumor companion diagnosis technology, with a total planned investment of 496.65 million yuan [2][3] - The actual investment was 367.55 million yuan, with a remaining surplus of 1.48 million yuan [3] Approval Process - The completion of the fundraising project and the use of surplus funds do not require board approval or explicit consent from the underwriter, as per the regulations [5]

Core Viewpoint - The company has approved the use of temporarily idle raised funds for cash management, not exceeding RMB 140 million, ensuring that it does not affect the normal implementation of fundraising investment plans [1][5]. Summary by Sections 1. Basic Situation of Raised Funds - The company raised a total of RMB 713.27 million from its initial public offering (IPO) by issuing 23.34 million shares at a price of RMB 30.56 per share, with all funds received and stored in a dedicated account [1]. 2. Investment Project Situation - The planned use of raised funds includes a project focused on the application development of a tumor companion diagnostic technology platform, with a total project cost of RMB 491.65 million and an intended use of RMB 453.62 million from the raised funds [2]. 3. Cash Management of Temporarily Idle Raised Funds - The company plans to use up to RMB 140 million of temporarily idle raised funds for cash management, ensuring that it does not impact the normal progress of fundraising investment projects. The funds can be used in a rolling manner within the specified limit [2][5]. - The investment period for this cash management is valid for 12 months from the date of board approval [3]. 4. Implementation Method - The board has authorized the chairman to exercise investment decision-making rights and sign relevant documents within the approved limit and validity period, with the finance department responsible for implementation [4]. 5. Distribution of Cash Management Earnings - Earnings from cash management will belong to the company and will be managed according to regulatory requirements, with funds returned to the dedicated account upon maturity [4]. 6. Review Procedures - The board and supervisory board have approved the cash management proposal, confirming compliance with relevant regulations and ensuring that it does not conflict with the construction of fundraising investment projects [5][6].

证券代码：688393 证券简称：安必平 公告编号：2025-037 广州安必平医药科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 "公司"）召开第四届董事会第九次会议,审议通过了《关于使用自有资金进行 现金管理的议案》，同意公司在确保不影响公司正常业务开展的情况下，使用额 度不超过人民币 22,000 万元的自有资金进行现金管理，用于购买安全性高、流 动性好、风险等级低的投资产品（包括但不限于结构性存款、定期存款、通知 存款、大额存单、协定存款等），且该等现金管理产品不得用于质押，不得实施 以证券投资为目的的投资行为。在上述额度内的资金可循环滚动使用。使用期 限自公司董事会审议通过之日起 12 个月内有效。 一、使用自有资金进行现金管理的概况 （一）现金管理目的 公司使用自有资金进行现金管理是为了提高公司资金使用效率，增加资产 收益，为公司及股东谋取更多回报，在保证公司正常经营所需流动资金的情况 下，提高资金利用效率，合理利用闲置资金，增加公司收益。 （三）现金管理额度及使用期限 公司计划使用不超过人民 ...

Core Viewpoint - The company plans to temporarily adjust the use of idle space from its fundraising investment project to enhance operational efficiency and generate additional income, while ensuring compliance with relevant regulations [1][3][4]. Group 1: Fundraising Overview - The company raised a net amount of RMB 639.9455 million after deducting issuance costs of RMB 73.3249 million during its initial public offering [1]. - The total amount allocated for the application development project based on tumor companion diagnostic technology is RMB 491.65 million, with RMB 453.62 million planned for use [2]. Group 2: Adjustment of Idle Space - Due to changes in the international environment and domestic economic slowdown, the company anticipates that some areas of its marketing service network upgrade project will be temporarily idle [2]. - The company intends to lease out the idle space to improve utilization efficiency and meet operational needs, which is expected to stabilize its business operations [3][4]. Group 3: Impact of the Adjustment - The decision to temporarily adjust the use of idle space is based on the company's actual operational situation and does not harm the interests of the company or its shareholders [3][4]. - The adjustment is in compliance with relevant regulations and is expected to enhance operational income without adversely affecting normal business operations [4]. Group 4: Review Procedures - The board of directors and the supervisory board have approved the proposal to temporarily lease out the idle space, confirming that the decision-making process was legal and effective [4].

民生证券股份有限公司关于广州安必平医药科技 股份有限公司使用暂时闲置募集资金进行现金管理的核查意见 民生证券股份有限公司（以下简称"保荐机构"或"民生证券"）作为广州 安必平医药科技股份有限公司（以下简称"安必平"或"公司"）首次公开发行 股票并上市持续督导的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》《上市公司募集资金监管规则》和《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关规定，对 安必平使用暂时闲置募集资金进行现金管理的相关事项进行了核查，发表核查 意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意广州安必平医药科技股份有限公 司首次公开发行股票注册的批复》（证监许可[2020]1489 号），广州安必平医药 科技股份有限公司首次向社会公开发行人民币普通股（A 股）2,334 万股，每股 发行价格 30.56 元，新股发行募集资金总额为 71,327.04 万元，扣除发行费用 上述募集资金已全部到位，并由中汇会计师事务所（特殊普通合伙）于 （中汇会验[2020]5523 号）。公司已对上述募集资金进行了专户存储，具体 ...